Description
SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptor (ERR) family — not a peptide, but a naphthalene-modified compound developed from the GSK4716 scaffold. It activates all three ERR subtypes (ERRα, ERRβ, and ERRγ) with the highest potency at ERRα. The naphthalene moiety replaces the isopropyl group of GSK4716, creating π-π stacking interactions with Phe328 in the ERRα ligand binding domain that improve receptor selectivity. ERRα is an orphan nuclear receptor and master regulator of mitochondrial biogenesis and cellular energy metabolism.
Key Characteristics
- ERRα is the primary high-potency target, with ERRβ and ERRγ activated at slightly lower potency. This pan-ERR activity profile differs from GSK4716, which is more ERRγ-selective; researchers selecting between the two compounds based on subtype specificity need to account for this distinction in study design
- DDIT4 gene upregulation is the key downstream marker of ERRα activation. DDIT4 is specifically induced by short bouts of aerobic exercise and serves as the initiating signal for the aerobic exercise transcriptional program; its upregulation by SLU-PP-332 in an ERRα-dependent manner is what anchors the compound’s classification as an exercise gene program activator
- Mitochondrial function and cellular respiration enhancement have been documented in skeletal muscle cell lines and in vivo mouse models — specifically, increased type IIa oxidative muscle fiber specification and mitochondrial electron transport chain gene expression
- Unlike MOTS-c, which activates mitochondrial-nuclear signaling through AMPK and targets metabolic stress adaptation, SLU-PP-332 activates ERRα at the nuclear receptor level to drive the aerobic exercise transcriptional program directly. These are two distinct entry points into mitochondrial biogenesis research
- All in vivo evidence derives from mouse models. No human pharmacokinetic or clinical trial data have been published
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. As a small molecule, SLU-PP-332 has different stability characteristics from peptide-based compounds. Avoid repeated freeze-thaw cycles and protect from light to maintain compound integrity.
FAQs
What is SLU-PP-332?
SLU-PP-332 is a synthetic small-molecule ERR pan-agonist — not a peptide — developed from the GSK4716 scaffold with a naphthalene modification that improves ERRα selectivity through π-π stacking interactions with Phe328 in the receptor’s ligand binding domain. It activates the DDIT4-mediated aerobic exercise gene program in skeletal muscle in an ERRα-dependent manner. All evidence is preclinical.
How does SLU-PP-332 differ from MOTS-c in mitochondrial research?
Both are studied for mitochondrial biogenesis and cellular energy signaling, but the mechanisms are distinct. MOTS-c is a mitochondrial-derived peptide that translocates to the nucleus under metabolic stress and activates AMPK-mediated signaling. SLU-PP-332 is a synthetic small molecule that directly activates ERRα — an orphan nuclear receptor — to drive the aerobic exercise transcriptional program, including DDIT4 upregulation and oxidative fiber specification. Researchers use MOTS-c for AMPK-mediated metabolic adaptation studies and SLU-PP-332 for ERRα-dependent exercise gene program research.
Why is ERRα considered an orphan nuclear receptor?
Orphan nuclear receptors are members of the nuclear receptor superfamily for which no endogenous ligand has been confirmed. ERRα regulates mitochondrial gene expression and energy metabolism in response to physiological signals. However, it does not have a known natural small-molecule ligand that activates it the way estrogen activates estrogen receptors. SLU-PP-332 is a synthetic agonist that binds the ERRα ligand-binding domain and activates its transcriptional activity.
